Does inhibition of glycolytic enzyme hexokinase II ( HK2 ) suppress lung tumor growth?
HK2 is a promising treatment target for NSCLC with Kras activating and p53 function loss.
Evaluation of Medicare prescription drug data suggests that the amount of missing claims for generic alendronate in 2008 was not substantial, and misclassification of exposure in studies examining alendronate use post-generic product availability should be minimal.